Production of recombinant protein therapeutics in cultivated mammalian cells
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Cultivated mammalian cells have become the dominant system for the production of recombinant proteins for clinical applications because of their capacity for proper protein folding, assembly and post-translational modification. Thus, the quality and efficacy of a protein can be superior when expressed in mammalian cells versus other hosts such as bacteria, plants and yeast. Recently, the productivity of mammalian cells cultivated in bioreactors has reached the gram per liter range in a number of cases, a more than 100-fold yield improvement over titers seen for similar processes in the mid-1980s. This increase in volumetric productivity has resulted mainly from improvements in media composition and process control. Opportunities still exist for improving mammalian cell systems through further advancements in production systems as well as through vector and host cell engineering.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Advances in cell engineering, process control, and media composition are credited with improving the volumetric yield of cell culture bioprocesses, making biopharmaceutical manufacturing more cost-effective and practical [8].”
From The role of Raman spectroscopy in biopharmaceuticals from development to manufacturing (2022) · cites this paper as [8]
In the citing paper
“Chinese hamster ovary (CHO) cells are one of the main cell lines used in the production of recombinant therapeutics (Wurm, 2004; see Grillberger et al., 2009 for examples of proteins produced in CHO cells).”
From Virus susceptibility of Chinese hamster ovary (CHO) cells and detection of viral contaminations by adventitious agent testing (2010) · cites this paper as Wurm, 2004
Citations
Cites
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451 · cited 1×
“In 1973, Graham and van der Eb showed that exposing cells to nanoparticles of DNA and calcium phosphate makes possible DNA transfer into cultivated mammalian cell”
BackgroundEpigenetic Codes for Heterochromatin Formation and Silencing
Richards, E. J., & Elgin, S. C. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00644-x · Cited by 871
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
How introns influence and enhance eukaryotic gene expression
Le Hir, H., Nott, A., & Moore, M. J. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00052-5 · Cited by 734
Bebbington, C. R., Renner, G., Thomson, S., King, D., Abrams, D., & Yarranton, G. T. (1992) · Nature Biotechnology · doi:10.1038/nbt0292-169 · Cited by 462 · cited 1×
“At a concentration of 10–100 μM MSX, resistant clones can be identified in selected NS0 cell populations that have amplified the transgene complex containing the GS gene and the desired gene(s) of interes”
BackgroundGenetic and physical linkage of exogenous sequences in transformed cells
Perucho, M., Hanahan, D., & Wigler, M. (1980) · Cell · doi:10.1016/0092-8674(80)90178-6 · Cited by 455 · cited 1×
“Nuclear ligases assure the covalent joining of individual plasmid DNA molecule”
BackgroundExpression of recombinant plasmids in mammalian cells Is enhanced by sodium butyrate
Gorman, C. M., Howard, B. H., & Reeves, R. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.21.7631 · Cited by 367 · cited 1×
“Another way to inhibit silencing is to block deacetylation of histones using butyrat”
BackgroundSilencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9
Mutskov, V., & Felsenfeld, G. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600013 · Cited by 296
Kim, S. J., Kim, N. S., Ryu, C. J., Hong, H. J., & Lee, G. M. (1998) · Biotechnology and Bioengineering · doi:10.1002/(sici)1097-0290(19980405)58:1<73::aid-bit8>3.0.co;2-r · Cited by 220 · cited 1×
“Thus, it might be advantageous to omit selective drugs once promising clonal cell lines have been identifie”
BackgroundLarge-scale transient expression in mammalian cells for recombinant protein production
Wurm, F., & Bernard, A. (1999) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(99)80027-5 · Cited by 203
Self-citation
Research works printed but not linked: 1
- Gorman, C.M., Howard, B.H. & Reeves, R. Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res. 11, 7631–7648 (1983). · DOI · Paper page
Cited by
Items 301–400 of 1,007
Cao, Y., Kimura, S., Itoi, T., Honda, K., Ohtake, H., & Omasa, T. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.24347 · Cited by 67
Le, K., Tan, C., Gupta, S., Guhan, T., Barkhordarian, H., Lull, J., Stevens, J. L., & Munro, T. P. (2018) · Biotechnology Progress · doi:10.1002/btpr.2690 · Cited by 75
“during selection, single cell subcloning, and the need to perform multiple screening assays to identify suitable production hosts.(1)”
BackgroundBrooks, S. A. (2006) · Expert Review of Proteomics · doi:10.1586/14789450.3.3.345 · Cited by 65
Antibody Isotypes for Tumor Immunotherapy
Kretschmer, A., Schwanbeck, R., Valerius, T., & Rösner, T. (2017) · Transfusion Medicine and Hemotherapy · doi:10.1159/000479240 · Cited by 83
Rajendra, Y., Hougland, M. D., Alam, R., Morehead, T. A., & Barnard, G. C. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25514 · Cited by 68
Lee, M., Lo, A., Cheung, P., Wong, D., & Chan, B. P. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.11.017 · Cited by 69
“This is because the secretion rate is a measure associated with the cost-effectiveness of using the microspheres as a 3D culture system for therapeutic protein production in pharmaceutical industrial applications [24] while the protein secretion level and pattern are more important parameters relevant for controlled r…”
BackgroundRapid recombinant protein production from piggyBac transposon-mediated stable CHO cell pools
Balasubramanian, S., Matasci, M., Kadlecová, Z., Baldi, L., Hacker, D. L., & Wurm, F. M. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.03.001 · Cited by 70
Self-citationGuo, D., Gao, A. E., Michels, D. A., Feeney, L., Eng, M., Chan, B., Laird, M. W., Zhang, B., Yu, X. C., Joly, J. C., et al. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22780 · Cited by 67
Han, Y., Liu, X., Hong, L., Li, S., Wu, B., Ye, L., Wang, Q.-W., & Chen, Z. (2006) · Journal of Bioscience and Bioengineering · doi:10.1263/jbb.102.430 · Cited by 67
Recombinant antibodies: Engineering and production in yeast and bacterial hosts
Jeong, K. J., Jang, S. H., & Velmurugan, N. (2010) · Biotechnology Journal · doi:10.1002/biot.201000381 · Cited by 72
“In the last decade, rapid progress has been made in mammalian cell cultivation, including the use of serumfree media, efficient gene expression, development of more powerful cell lines, and optimization of culture and reactor [21, 22].”
BackgroundBioreactors for cell therapies: Current status and future advances
Eaker, S. S., Abraham, E., Allickson, J. G., Brieva, T. A., Baksh, D., Heathman, T. R. J., Mistry, B., & Zhang, N. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.09.011 · Cited by 67
New Insights into Cell Culture Technology
(2017) · InTech eBooks · doi:10.5772/62590 · Cited by 65
Burgio, S., Noori, L., Marino Gammazza, A., Campanella, C., Logozzi, M., Fais, S., Bucchieri, F., Cappello, F., & Caruso Bavisotto, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155432 · Cited by 58
Emerging application of hydrocyclone in biotechnology and food processing
Ji, L., Paul, P., Shanbhag, B. K., Dixon, I., Kuang, S., & He, L. (2022) · Separation and Purification Technology · doi:10.1016/j.seppur.2022.122992 · Cited by 70
Blueprint for antibody biologics developability
Mieczkowski, C., Zhang, X., Lee, D., Nguyen, K., Lv, W., Wang, Y., Zhang, Y., Way, J., & Gries, J. (2023) · mAbs · doi:10.1080/19420862.2023.2185924 · Cited by 76
“While a final lead may be selected based on transiently expressed material, material from stable cell-lines may express at higher purity and yield and have more representative core glycosylation profiles.(93) A final lead should have acceptable yield and purity following all platform purification steps, such as ProA a…”
BackgroundKishishita, S., Katayama, S., Kodaira, K., Takagi, Y., Matsuda, H., Okamoto, H., Takuma, S., Hirashima, C., & Aoyagi, H. (2015) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2014.11.022 · Cited by 76
Engineering eukaryotic protein factories
Schröder, M. (2007) · Biotechnology Letters · doi:10.1007/s10529-007-9524-1 · Cited by 70
“However, cell specific productivities remained nearly constant during this time (Wurm 2004).”
BackgroundZhou, H., Liu, Z., Sun, Z., Huang, Y., & Yu, W. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.03.020 · Cited by 78
CHO gene expression profiling in biopharmaceutical process analysis and design
Schaub, J., Clemens, C., Schorn, P., Hildebrandt, T., Rust, W., Mennerich, D., Kaufmann, H., & Schulz, T. W. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22549 · Cited by 63
Lee, C. J., Seth, G., Tsukuda, J., & Hamilton, R. W. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.22126 · Cited by 65
Examining the sources of variability in cell culture media used for biopharmaceutical production
McGillicuddy, N., Floris, P., Albrecht, S., & Bones, J. (2017) · Biotechnology Letters · doi:10.1007/s10529-017-2437-8 · Cited by 74
Production of Recombinant Pharmaceutical Proteins
Gupta, V., Sengupta, M., Prakash, J., & Tripathy, B. C. (2016) · Springer eBooks · doi:10.1007/978-981-10-0875-7_4 · Cited by 77
“CHO cells are relatively easy to manipulate and their properties favor large-scale production in them [ 24 ] .”
BackgroundA Simple Method to Reduce both Lactic Acid and Ammonium Production in Industrial Animal Cell Culture
Freund, N., & Croughan, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020385 · Cited by 56
Cell culture medium improvement by rigorous shuffling of components using media blending
Jordan, M., Voisard, D., Berthoud, A., Tercier, L., Kleuser, B., Baer, G., & Broly, H. (2012) · Cytotechnology · doi:10.1007/s10616-012-9462-1 · Cited by 72
“Dramatic improvements of titers of recombinant proteins (g/L) have been achieved during the last 20 years by process and medium optimization (Wurm 2004).”
BackgroundGaillet, B., Gilbert, R., Broussau, S., Pilotte, A., Malenfant, F., Mullick, A., Garnier, A., & Massie, B. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22698 · Cited by 59
“Furthermore, CHO cells can grow to very high densities in serum free medium suspension cultures allowing for scale up in bioreactors (>10,000 L) (Andersen and Krummen, 2002; O’Callaghan and James, 2008; Wurm, 2004).”
Farrell, A., McLoughlin, N., Milne, J. J., Marison, I. W., & Bones, J. (2014) · Journal of Proteome Research · doi:10.1021/pr500219b · Cited by 63
Advances in Protein-Based Materials: From Origin to Novel Biomaterials
Choi, S. M., Chaudhry, P., Zo, S. M., & Han, S. S. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-0950-2_10 · Cited by 67
Shen, D., Kiehl, T. R., Khattak, S. F., Li, Z. J., He, A., Kayne, P. S., Patel, V., Neuhaus, I. M., & Sharfstein, S. T. (2010) · Biotechnology Progress · doi:10.1002/btpr.398 · Cited by 60
“7 days.(1) In contrast, in 2004, typical final cell densities were 10 10(6), and cultures were maintained for almost 3 weeks with a high level of viability, yielding a 17-fold increase in the integrated viable cell number.”
BackgroundAnimal cell technology: from biopharmaceuticals to gene therapy
(2008) · Choice Reviews Online · doi:10.5860/choice.46-1453 · Cited by 63
Advances in improving mammalian cells metabolism for recombinant protein production
Altamirano, C., Berrios, J., Vergara, M., & Becerra, S. (2013) · Electronic Journal of Biotechnology · doi:10.2225/vol16-issue3-fulltext-2 · Cited by 60
“The use of CHO cells has been favoured over other cell lines due to their ability to produce r-proteins with complex post-translational modifications (e.g., glycosylation), which are essential to biologic functionality and security (Wurm, 2004).”
BackgroundNiazi, S. K., & Magoola, M. (2023) · Biologics · doi:10.3390/biologics3040021 · Cited by 68
“This absence can compromise the mAb’s efficacy [29].”
BackgroundMetabolite profiling of CHO cells: Molecular reflections of bioprocessing effectiveness
Sellick, C. A., Croxford, A. S., Maqsood, A. R., Stephens, G. M., Westerhoff, H. V., Goodacre, R., & Dickson, A. J. (2015) · Biotechnology Journal · doi:10.1002/biot.201400664 · Cited by 60
“antibodies) by their nature are complex molecules requiring specific post-translational modifications for activity [1].”
BackgroundHigh-throughput ClonePix FL analysis of mAb-expressing clones using the UCOE expression system
Hou, J. J. C., Hughes, B. S., Smede, M., Leung, K. M., Levine, K. B., Rigby, S., Gray, P. P., & Munro, T. P. (2014) · New Biotechnology · doi:10.1016/j.nbt.2014.02.002 · Cited by 70
“high-expressing clones can be more than 3–6 months [6].”
Inducible product gene expression technology tailored to bioprocess engineering
Weber, W., & Fussenegger, M. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.09.002 · Cited by 70
Hartenbach, S., Baba, M. D.-E., Weber, W., & Fussenegger, M. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm652 · Cited by 63
“to prevent prohibitive downstream processing and licensing procedures ( 33 ), the gene therapy community dreams of capturing pathologic signals which can be converted into a well-tuned therapeutic intervention.”
BackgroundTreier, K., Hansen, S. K., Richter, C. G., Diederich, P., Hubbuch, J. J., & Lester, P. M. (2012) · Biotechnology Progress · doi:10.1002/btpr.1533 · Cited by 63
Sharker, S. M., & Rahman, A. (2020) · Current Drug Discovery Technologies · doi:10.2174/1570163817666200312102137 · Cited by 69
Ho, S. C. L., Mariati, Yeo, J. H. M., Fang, S. G., & Yang, Y. (2014) · Molecular Biotechnology · doi:10.1007/s12033-014-9809-2 · Cited by 66
“Mammalian cells, such as Chinese hamster ovary cells (CHO), are predominant for commercial production of therapeutic proteins because of their capacity to perform proper protein folding, assembly, and post-translational modifications (1, 2).”
BackgroundHigh level expression of functional human IgMs in human PER.C6® cells
Tchoudakova, A., Hensel, F., Murillo, A., Eng, B., Foley, M., Smith, L., Schoenen, F., Hildebrand, A., Kelter, A.-R., Ilag, L. L., et al. (2009) · mAbs · doi:10.4161/mabs.1.2.7945 · Cited by 63
Strategies for Whole Lung Tissue Engineering
Calle, E. A., Ghaedi, M., Sundaram, S., Sivarapatna, A., Tseng, M. K., & Niklason, L. E. (2014) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2014.2314261 · Cited by 68
“industry), steady advances have increased the bioprocess protein yield 100-fold since the mid-1980s [152], [153].”
BackgroundHigh productivity of human recombinant beta-interferon from a low-temperature perfusion culture
Rodriguez, J., Spearman, M. A., Tharmalingam, T., Sunley, K., Lodewyks, C. L., Huzel, N. J., & Butler, M. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.09.959 · Cited by 67
Utilization and evaluation of CHO‐specific sequence databases for mass spectrometry based proteomics
Meleady, P., Hoffrogge, R., Henry, M., Rupp, O., Bort, J. H., Clarke, C., Brinkrolf, K., Kelly, S., Müller, B., Doolan, P., et al. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.24476 · Cited by 55
“…culture processes and the concomitant improvements in media formulation and bioreactor design have resulted in a substantial increase in yields (Wurm, 2004) and the ability of CHO cells to adapt to different media and growth conditions has enabled the isolation of a variety of cell types…”
BackgroundSynthetic polymers for biopharmaceutical delivery
Magnusson, J. P., Saeed, A. O., Fernández‐Trillo, F., & Alexander, C. (2011) · Polymer Chemistry · doi:10.1039/c0py00210k · Cited by 71
Sellick, C. A., Hansen, R., Jarvis, R. M., Maqsood, A. R., Stephens, G. M., Dickson, A. J., & Goodacre, R. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22707 · Cited by 60
Tamura, A., Nishi, M., Kobayashi, J., Nagase, K., Yajima, H., Yamato, M., & Okano, T. (2012) · Biomacromolecules · doi:10.1021/bm300256e · Cited by 62
Goldrick, S., Lee, K., Spencer, C., Holmes, W., Kuiper, M., Turner, R., & Farid, S. S. (2018) · Biotechnology Journal · doi:10.1002/biot.201700607 · Cited by 56
Kornecki, M., & Strube, J. (2018) · Bioengineering · doi:10.3390/bioengineering5010025 · Cited by 61
Differential effect of exocytic SNAREs on the production of recombinant proteins in mammalian cells
Peng, R., Abellan, E., & Fussenegger, M. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.22986 · Cited by 61
“…have been made to develop strategies for producing large amounts of recombinant proteins in transgenic mammalian cells, in particular by means of transcription- and translation-based engineering (Barnes and Dickson, 2006; Fussenegger and Hauser, 2007; Weber and Fussenegger, 2007; Wurm, 2004).”
BackgroundKarst, D. J., Steinhoff, R., Kopp, M. R. G., Serra, E., Šoóš, M., Zenobi, R., & Morbidelli, M. (2017) · Biotechnology Progress · doi:10.1002/btpr.2421 · Cited by 63
Effects of high passage cultivation on CHO cells: a global analysis
Beckmann, T., Krämer, O. H., Klausing, S., Heinrich, C., Thüte, T., Büntemeyer, H., Hoffrogge, R., & Noll, T. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3806-1 · Cited by 73
“Mammalian cell lines are the dominant biological system for the production of biopharmaceutical proteins today (Wurm 2004).”
BackgroundInfluentialVergara, M., Becerra, S., Berrios, J., Osses, N., Reyes, J., Rodríguez-Moyá, M., Gonzalez, R., & Altamirano, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093865 · Cited by 58
Cell line profiling to improve monoclonal antibody production
Kang, S., Ren, D., Xiao, G., Daris, K., Buck, L., Enyenihi, A. A., Zubarev, R. A., Bondarenko, P. V., & Deshpande, R. R. (2013) · Biotechnology and Bioengineering · doi:10.1002/bit.25141 · Cited by 68
Braasch, K., Nikolic‐Jaric, M., Cabel, T., Salimi, E., Bridges, G. E., Thomson, D. J., & Butler, M. (2013) · Biotechnology and Bioengineering · doi:10.1002/bit.24976 · Cited by 60
“The ability to prolong the viability of cells at high density is a key factor in enhancing the productivity of a mammalian cell bioprocess (Wurm, 2004).”
BackgroundExpression of Myocilin Mutants Sensitizes Cells to Oxidative Stress-Induced Apoptosis
Joe, M. K., & Tomarev, S. I. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090853 · Cited by 59
“Generally, expression levels of transgenes can be profoundly affected by position effect variation.(43) It is possible that the I477N transgene may be inserted near an enhancer, which would explain higher inducibility of this mutant line compared with other lines.”
Wong, H.-L., Wang, M., Cheung, P., Yao, K., & Chan, B. P. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.08.016 · Cited by 59
“Mammalian cell culture technology in production of recombinant therapeutic proteins has been developed over years [1].”
BackgroundEliminating tyrosine sequence variants in CHO cell lines producing recombinant monoclonal antibodies
Feeney, L., Carvalhal, V., Yu, X., Chan, B., Michels, D. A., Wang, Y. J., Shen, A. Y., Ressl, J., Dusel, B., & Laird, M. W. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.24759 · Cited by 67
“In order to meet the market demand for therapeutic mAbs, significant advances have been made in cell line development, cell culture media optimization and bioprocess optimization (Kelley, 2009; Li et al., 2010; Low et al., 2007; Vijayasankaran et al., 2010; Wurm, 2004).”
BackgroundKameyama, Y., Kawabe, Y., Ito, A., & Kamihira, M. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22619 · Cited by 58
A system for site-specific integration of transgenes in mammalian cells
Chi, X., Zheng, Q., Jiang, R., Chen-Tsai, R. Y., & Kong, L.-J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219842 · Cited by 74
Pichler, J., Galosy, S. S., Mott, J. E., & Borth, N. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22946 · Cited by 72
“…importance and the increasing demand for mAb therapeutics, efforts for optimizing all aspects of the manufacturing process are being explored. mAbs are multimeric, glycosylated proteins and their expression by mammalian cells is a complex multi-step process (Birch and Racher, 2006; Wurm, 2004).”
BackgroundUsing cell engineering and omic tools for the improvement of cell culture processes
Kuystermans, D., Krampe, B., Swiderek, H., & Al-Rubeai, M. (2007) · Cytotechnology · doi:10.1007/s10616-007-9055-6 · Cited by 55
“2005), baby hamster kidney (BHK) (Wurm 2004) and more recently, the human retina derived (PerC6) (Jones et al.”
BackgroundProcess chromatography : Five decades of innovation
Curling, J. M., & Gottschalk, U. (2007) · Biopharm international · Cited by 58
Perez, E. M., Foley, J., Tison, T., Silva, R., & Ogembo, J. G. (2016) · Oncotarget · doi:10.18632/oncotarget.13770 · Cited by 58
“Although no specific nAbs to EBV gL or gB have been reported in patients to date [11], gB-specific nAbs have been tested in several clinical trials to prevent neonatal cytomegalovirus infection [65-67].”
BackgroundThe present state of the art in expression, production and characterization of monoclonal antibodies
Gaughan, C. L. (2015) · Molecular Diversity · doi:10.1007/s11030-015-9625-z · Cited by 67
“Somemethods of optimization include single component titration, spent medium analysis and medium blending [32].”
BackgroundInfluentialAnsorge, S., Esteban, G., & Schmid, G. (2010) · Cytotechnology · doi:10.1007/s10616-010-9267-z · Cited by 59
“Fed-batch processes continue to be the most relevant culture mode for the vast majority of high-yielding commercial bioprocesses due to their ease of operation and reliability ( Wurm 2004; Chee Furng Wong et al. 2005).”
BackgroundKonno, Y., Kobayashi, Y., Takahashi, K. L., Takahashi, E., Sakae, S., Wakitani, M., Yamano, K., Suzawa, T., Yano, K., Ohta, T., et al. (2011) · Cytotechnology · doi:10.1007/s10616-011-9377-2 · Cited by 60
“This is because different host cell lines exhibit distinct glycosylation patterns (especially fucosylation), and MAbs produced in a particular host will demonstrate a specific ADCC activity (Shields et al. 2002; Shinkawa et al. 2003; Wurm 2004).”
Background'Molecular farming' of antibodies in plants
Schillberg, S., Fischer, R., & Emans, N. (2003) · Die Naturwissenschaften · doi:10.1007/s00114-002-0400-5 · Cited by 68
“antibody production systems which are based on the large-scale culture of microbes or animal cells (Chu and Robinson, 2001; Wurm, 2004).”
BackgroundLakshmanan, M., Kok, Y. J., Lee, A., Kyriakopoulos, S., Lim, H. L., Teo, G., Poh, S. L., Tang, W. Q., Hong, J. K., Tan, A. H., et al. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.27014 · Cited by 62
Strategies for recombinant production of antimicrobial peptides with pharmacological potential
Sampaio de Oliveira, K. B., Leite, M. L., Rodrigues, G. R., Duque, H. M., da Costa, R. A., Cunha, V. A., de Loiola Costa, L. S., da Cunha, N. B., Franco, O. L., & Dias, S. C. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1764347 · Cited by 55
“be used to produce recombinant protein for biomedical and pharmaceutical research [196,198,200,201,203,204].”
BackgroundRefolding of biotech therapeutic proteins expressed in bacteria: review
Rathore, A. S., Bade, P. D., Joshi, V. S., Pathak, M., & Pattanayek, S. K. (2013) · Journal of Chemical Technology & Biotechnology · doi:10.1002/jctb.4152 · Cited by 59
HaloTag-based purification of functional human kinases from mammalian cells
Ohana, R. F., Hurst, R., Vidugirienė, J., Slater, M. R., Wood, K. V., & Urh, M. (2010) · Protein Expression and Purification · doi:10.1016/j.pep.2010.11.014 · Cited by 56
Zhang, F., Sun, X., Yi, X., & Zhang, Y. (2006) · Cytotechnology · doi:10.1007/s10616-006-9010-y · Cited by 56
“One wellestablished strategy is to introducing GS gene into a cell line, such as NS0 and CHO cells, to enable the cells to grow independently of the presence of glutamine in the medium (Dempsey et al. 2003; Wurm 2004).”
BackgroundKshirsagar, R., McElearney, K., Gilbert, A., Sinacore, M., & Ryll, T. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.24511 · Cited by 59
High‐throughput screening and selection of mammalian cells for enhanced protein production
Priola, J. J., Calzadilla, N., Baumann, M., Borth, N., Tate, C. G., & Betenbaugh, M. J. (2016) · Biotechnology Journal · doi:10.1002/biot.201500579 · Cited by 70
“By far the most common, traditional method to identify highexpressing clones is the process of limiting dilution cloning [5, 24, 25].”
BackgroundMethodPristovšek, N., Nallapareddy, S., Grav, L. M., Hefzi, H., Lewis, N. E., Rugbjerg, P., Hansen, H. G., Lee, G. M., Andersen, M. R., & Kildegaard, H. F. (2019) · ACS Synthetic Biology · doi:10.1021/acssynbio.8b00453 · Cited by 59
González‐Leal, I. J., Carrillo‐Cocom, L. M., Ramírez‐Medrano, A., López‐Pacheco, F., Bulnes‐Abundis, D., Webb-Vargas, Y., & Álvarez, M. M. (2011) · Biotechnology Progress · doi:10.1002/btpr.674 · Cited by 58
“The selected target value is a representative value for highly productive cells in commercial high-cell-concentration fedbatch or perfusion processes.(2) It should be noted that His, Ser, and Leu are the three amino acids that are most rapidly consumed, as well as the amino acids (in particular, His) with the highest…”
BackgroundThe art of antibody process development
Steinmeyer, D. E., & McCormick, E. L. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.04.005 · Cited by 56
Perfusion culture of Chinese Hamster Ovary cells for bioprocessing applications
MacDonald, M. A., Nöbel, M., Roche Recinos, D., Martínez, V. S., Schulz, B. L., Howard, C. B., Baker, K., Shave, E., Lee, Y. Y., Marcellin, E., et al. (2022) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2021.1998821 · Cited by 55
Enhanced glycoprotein production in HEK-293 cells expressing pyruvate carboxylase
Henry, O., & Durocher, Y. (2011) · Metabolic Engineering · doi:10.1016/j.ymben.2011.05.004 · Cited by 63
Folding aggregated proteins into functionally active forms
Świętnicki, W. (2006) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2006.05.011 · Cited by 60
HaloTag, a Platform Technology for Protein Analysis
Urh, M. (2012) · Current Chemical Genomics · doi:10.2174/1875397301206010072 · Cited by 55
Azevedo, A. M., Rosa, P. A. J., Ferreira, I. F., de Vries, J., Visser, T., & Aires-Barros, M. R. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2008.11.014 · Cited by 54
A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies
Jones, M. L., Seldon, T. A., Smede, M., Linville, A., Chin, D. Y., Barnard, R. T., Mahler, S. M., Munster, D. J., Hart, D. N. J., Gray, P. P., et al. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.02.001 · Cited by 54
“Most therapeutic recombinant mAbs aremembers of the IgG family and owing to their large size and complex glycosylation patterns, these molecules are currently produced in mammalian cells, with the vast majority utilizing Chinese Hamster Ovary (CHO) cells as the production host (Wurm, 2004).”
BackgroundDeveloping genomic platforms for Chinese hamster ovary cells
Kantardjieff, A., Nissom, P. M., Chuah, S. H., Yusufi, F. N. K., Jacob, N. M., Mulukutla, B. C., Yap, M. G. S., & Hu, W. (2009) · Biotechnology Advances · doi:10.1016/j.biotechadv.2009.05.023 · Cited by 69
Taschwer, M., Hackl, M., Bort, J. A. H., Leitner, C., Kumar, N., Puc, U., Grass, J., Pabst, M., Kunert, R., Altmann, F., et al. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.11.014 · Cited by 54
Stine, J. M., Beardslee, L. A., Sathyam, R. M., Bentley, W. E., & Ghodssi, R. (2020) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2020.128381 · Cited by 55
“Monoclonal antibodies are produced in large fully automated bioreactors and are synthesized by recombinant cell lines (primarily of the Chinese hamster ovary, CHO) cultivated in carefully designed cell culture media [4].”
BackgroundLanza, A. M., Kim, D. S., & Alper, H. S. (2013) · Biotechnology Journal · doi:10.1002/biot.201200364 · Cited by 61
“KGaA, Weinheim ing of the integrated transgene can occur over time [11], especially when selection pressure is relieved, which results in undesirable, decreased expression of a gene of interest.”
BackgroundMethodResultInfluentialExploring the effect of mild hypothermia on CHO cell productivity
Becerra, S., Berríos, J., Osses, N., & Altamirano, C. (2011) · Biochemical Engineering Journal · doi:10.1016/j.bej.2011.10.003 · Cited by 64
Elseberg, C. L., Leber, J., Salzig, D., Wallrapp, C., Kassem, M. S., Kraume, M., & Czermak, P. (2012) · The International Journal of Artificial Organs · doi:10.5301/ijao.5000077 · Cited by 53
“These complex processes must satisfy good manufacturing practice (GMP) requirements specified by the authorities (5-10).”
BackgroundHuman cell lines for the production of recombinant proteins: on the horizon
Fliedl, L., Grillari, J., & Grillari‐Voglauer, R. (2014) · New Biotechnology · doi:10.1016/j.nbt.2014.11.005 · Cited by 59
Padawer, I., Ling, W. L. W., & Bai, Y. (2013) · Biotechnology Progress · doi:10.1002/btpr.1719 · Cited by 53
“Extending the cell culture for as long as possible in order to achieve the highest possible titers is limited by declining cell viabilities, diminishing productivities and protein quality, and perhaps most importantly by manufacturing plant capacity.(4) In order to achieve an accelerated production timeline, high prod…”
Phenotypic variation during cloning procedures: Analysis of the growth behavior of clonal cell lines
Barnes, L. M., Moy, N., & Dickson, A. J. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20856 · Cited by 53
“This is largely due to the fact thatmammalian cells have the ability to perform post-translational modifications of the correct fidelity, which is essential if the protein is to be used for treatment or diagnosis (Werner et al., 1998, Wurm, 2004).”
BackgroundUbiquitous Chromatin-opening Elements (UCOEs): Applications in biomanufacturing and gene therapy
Neville, J. J., Orlando, J., Mann, K., McCloskey, B., & Antoniou, M. N. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.05.004 · Cited by 60
“CHO cells are currently the most widely used mammalian host for recombinant protein production due to their well-established safety and simplicity of use (Jostock and Knopf, 2012; Wurm, 2004).”
BackgroundKo, P., Misaghi, S., Hu, Z., Zhan, D., Tsukuda, J., Yim, M., Sanford, M., Shaw, D., Shiratori, M., Snedecor, B., et al. (2017) · Biotechnology Progress · doi:10.1002/btpr.2594 · Cited by 53
“During the past 20 years, Chinese hamster ovary (CHO) cells have been the most commonly used platform to express various forms of therapeutic proteins and antibodies.(1) Over time, different guidelines have been applied to regulate the process of drug development in CHO cells including cell line development (CLD) and…”
BackgroundJosephides, D. N., Davoli, S., Whitley, W., Ruis, R., Salter, R., Gokkaya, S., Vallet, M., Matthews, D., Benazzi, G., Shvets, E., et al. (2020) · SLAS TECHNOLOGY · doi:10.1177/2472630319892571 · Cited by 53
“In cell line development, the main challenge is to screen large cell populations for their productivity.(4) After the antibody sequence has been defined, a pool of cells is transfected and, after selection, the clones with the higher titer and better yield must be selected and isolated.”
BackgroundCharacterization of a novel modification on IgG2 light chain
Martinez, T., Pace, D. L., Brady, L. J., GERHART, M. J., & Balland, A. (2007) · Journal of Chromatography A · doi:10.1016/j.chroma.2007.04.050 · Cited by 53
Lattenmayer, C., Trummer, E., Schriebl, K., Vorauer‐Uhl, K., Mueller, D., Katinger, H. W. D., & Kunert, R. (2006) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2006.12.016 · Cited by 53
Xing, Z., Li, Z., Chow, V., & Lee, S. S. (2008) · Biotechnology Progress · doi:10.1021/bp070466m · Cited by 52
Marchant, R. J., Al‐Fageeh, M. B., Underhill, M. F., Racher, A. J., & Smales, C. M. (2008) · Molecular Biotechnology · doi:10.1007/s12033-008-9032-0 · Cited by 60
“Since the inception of these cell lines for the production of recombinant proteins, the level of target protein that such mammalian expression systems can produce has been enhanced many fold, largely through the empirical optimization of expression vectors, cell culture medium, and process development [ 4 ].”
BackgroundMammalian cells as biopharmaceutical production hosts in the age of omics
Dietmair, S., Nielsen, L. K., & Timmins, N. E. (2011) · Biotechnology Journal · doi:10.1002/biot.201100369 · Cited by 62
“Although optimization of medium composition and culture conditions has delivered significant improvements in volumetric product titers over the past few decades, cell-specific productivity (q) has seen little increase since the 1990s [1].”
BackgroundCervera, L., Gutiérrez-Granados, S., Berrow, N. S., Segura, M. M., & Gòdia, F. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25503 · Cited by 61
Metadata
- Authors
- Wurm, F. M.
- Affiliations
- École Polytechnique Fédérale de Lausanne (CH)
- Corresponding author
- Wurm, Florian M
- ORCID
- Wurm, Florian M
- Venue
- Nature Biotechnology
- Published
- 2004-11
- Volume
- 22
- Issue
- 11
- Pages
- 1393-1398
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2118540273
- Cited by
- 2,032
- References
- 52
- Citations by year
- 2026: 52 · 2025: 51 · 2024: 66 · 2023: 66 · 2022: 64 · 2021: 77 · 2020: 89 · 2019: 114 · 2018: 162 · 2017: 118 · 2016: 95 · 2015: 135 · 2014: 108 · 2013: 145 · 2012: 111
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Transgenic Plants and Applications
- Keywords
- recombinant therapeutic proteins, mammalian cell culture, bioreactors, protein folding, post-translational modification, volumetric productivity, culture medium optimization, process control, vector engineering, host cell engineering
- MeSH terms
- Animals, Cells, Cultured, Humans, Mammals, Recombinant Proteins, Transfection, Protein Engineering, Cell Culture Techniques, Bioreactors, Genetic Enhancement
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.